Molecular biomarkers in multiple sclerosis

Por Ziemssen, Tjalf, Akgün, Katja, Brück, Wolfgang
Publicado no J Neuroinflammation (2019)

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies

Por Akgün, Katja, Essner, Ute, Seydel, Cordula, Ziemssen, Tjalf
Publicado no J Cent Nerv Syst Dis (2019)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration

Por Sehr, Tony, Akgün, Katja, Haase, Rocco, Ziemssen, Tjalf
Publicado no Front Neurol (2020)

Should We Use Clinical Tools to Identify Disease Progression?

Por Inojosa, Hernan, Proschmann, Undine, Akgün, Katja, Ziemssen, Tjalf
Publicado no Front Neurol (2021)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients

Por Kaufmann, Maxi, Haase, Rocco, Proschmann, Undine, Ziemssen, Tjalf, Akgün, Katja
Publicado no Front Immunol (2018)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

Por Kaufmann, Maxi, Haase, Rocco, Proschmann, Undine, Ziemssen, Tjalf, Akgün, Katja
Publicado no Front Neurol (2018)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis

Por Akgün, Katja, Blankenburg, Judith, Marggraf, Michaela, Haase, Rocco, Ziemssen, Tjalf
Publicado no Front Immunol (2020)

Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis

Por Jin, Mengmeng, Günther, Rene, Akgün, Katja, Hermann, Andreas, Ziemssen, Tjalf
Publicado no Sci Rep (2020)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis

Por Akgün, Katja, Metz, Imke, Kitzler, Hagen H., Brück, Wolfgang, Ziemssen, Tjalf
Publicado no Ther Adv Neurol Disord (2018)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis

Por Inojosa, Hernan, Eisele, Judith, Proschmann, Undine, Zeissig, Sebastian, Akgün, Katja, Ziemssen, Tjalf
Publicado no Front Cell Dev Biol (2020)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

Por Li, Kai, Konofalska, Urszula, Akgün, Katja, Reimann, Manja, Rüdiger, Heinz, Haase, Rocco, Ziemssen, Tjalf
Publicado no Front Neurosci (2017)

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS

Por Akgün, Katja, Kretschmann, Nicole, Haase, Rocco, Proschmann, Undine, Kitzler, Hagen H., Reichmann, Heinz, Ziemssen, Tjalf
Publicado no Neurol Neuroimmunol Neuroinflamm (2019)

Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Por Moser, Tobias, Schwenker, Kerstin, Seiberl, Michael, Feige, Julia, Akgün, Katja, Haschke‐Becher, Elisabeth, Ziemssen, Tjalf, Sellner, Johann
Publicado no Ann Clin Transl Neurol (2020)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting

Por Rodriguez-Leal, Francisco Alejandro, Haase, Rocco, Akgün, Katja, Eisele, Judith, Proschmann, Undine, Schultheiss, Thorsten, Kern, Raimar, Ziemssen, Tjalf
Publicado no Ther Adv Chronic Dis (2019)

The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice

Por Trentzsch, Katrin, Weidemann, Marie Luise, Torp, Charlotte, Inojosa, Hernan, Scholz, Maria, Haase, Rocco, Schriefer, Dirk, Akgün, Katja, Ziemssen, Tjalf
Publicado no Front Neurosci (2020)